Markets

Why Receptos Inc. Shares Rocketed Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Receptos , a clinical-stage biopharmaceutical company focused on developing therapies to treat immune disorders, surged higher by as much as 26% after the company released an abstract including additional data from its RADIANCE study of relapsing multiple sclerosis drug RPC1063. It also plans to present this additional data at the MS Boston conference this coming Saturday.

So what: According to the additional abstract released today, RPC1063 was shown to cause a 53% annualized relapse reduction in the highest dosing group, which, as Investors Business Dailypointed out , is right in line with some recently approved multiple sclerosis therapies such as Biogen Idec 's Tecfidera. This is simply additional good news for Receptos which announced in June that RPC1063 resulted in an 86% reduction in lesion for patients with relapsing multiple sclerosis. If RPC1063 proves to be as effective as Tecfidera at reducing relapse rates it could eat into Biogen's rapidly growing market share.

Now what: We've certainly witnessed steady improvement in MS-based lesion reduction and lower relapses of MS incidence in recent years (in clinical trials) through the development of new oral meds, but the need for more options and better medications is still clearly there. Today's response data clearly puts Receptos on the radar of investors looking to buy into drugs which have the potential to drastically change patients' quality of life for the better. Of course, investors should also keep in the back of their minds that Receptos is still wholly clinical and losing money, but is now pushing a $1.6 billion valuation, so this optimism may well be priced in already.

Though RPC1063 may offer plenty of potential, this revolutionary technology could leave Receptos eating dust!

The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .

The article Why Receptos Inc. Shares Rocketed Higher originally appeared on Fool.com.

Sean Williamshas no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BIIB

Other Topics

Stocks